USA - NASDAQ:CLPT - US18507C1036 - Common Stock
The current stock price of CLPT is 23.68 USD. In the past month the price decreased by -5.47%. In the past year, price increased by 83.71%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.98 | 216.98B | ||
| ISRG | INTUITIVE SURGICAL INC | 61.56 | 190.00B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.09 | 149.02B | ||
| SYK | STRYKER CORP | 28.71 | 141.06B | ||
| MDT | MEDTRONIC PLC | 16.45 | 116.69B | ||
| BDX | BECTON DICKINSON AND CO | 12.57 | 51.42B | ||
| IDXX | IDEXX LABORATORIES INC | 52.33 | 50.28B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.48 | 49.01B | ||
| RMD | RESMED INC | 26.41 | 36.81B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.34 | 34.24B | ||
| DXCM | DEXCOM INC | 40.12 | 26.75B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.23 | 26.26B | 
 Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 115 full-time employees. The company went IPO on 2019-07-03. The firm provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The firm is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The firm also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
CLEARPOINT NEURO INC
120 S. Sierra Avenue, Suite 100
Solana Beach CALIFORNIA 92618 US
CEO: Joseph M. Burnett
Employees: 115
Phone: 19499006833
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 115 full-time employees. The company went IPO on 2019-07-03. The firm provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The firm is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The firm also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
The current stock price of CLPT is 23.68 USD. The price decreased by -1.78% in the last trading session.
CLPT does not pay a dividend.
CLPT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CLPT.
CLEARPOINT NEURO INC (CLPT) currently has 115 employees.
CLEARPOINT NEURO INC (CLPT) will report earnings on 2025-11-11.
ChartMill assigns a technical rating of 8 / 10 to CLPT. When comparing the yearly performance of all stocks, CLPT is one of the better performing stocks in the market, outperforming 96.4% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to CLPT. The financial health of CLPT is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CLPT reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS decreased by -14.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.35% | ||
| ROE | -112.56% | ||
| Debt/Equity | 1.46 | 
8 analysts have analysed CLPT and the average price target is 29.58 USD. This implies a price increase of 24.92% is expected in the next year compared to the current price of 23.68.
For the next year, analysts expect an EPS growth of -17.3% and a revenue growth 18.26% for CLPT